Stock ONC ONCOLYTICS BIOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Oncolytics Biotech Inc.

Equities

ONC

CA6823108759

Market Closed - Toronto S.E.
Other stock markets
 21:00:00 10/05/2024 BST 		5-day change 1st Jan Change
1.59 CAD -5.92% Intraday chart for Oncolytics Biotech Inc. -0.62% -11.17%
05-09 Oncolytics Biotech Reports a First-Quarter Loss of Near $7 Million MT
05-09 Transcript : Oncolytics Biotech Inc., Q1 2024 Earnings Call, May 09, 2024

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oncolytics Biotech Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
AQ
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights
AQ
Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
PR
Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
AQ
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
AQ
Oncolytics Biotech Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
AQ
Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
AQ
Oncolytics Biotech : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2024 MANAGEMENT INFORMATION CIRCULAR - Form 6-K
PU
Oncolytics Biotech Advances toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
AQ
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
PR
Oncolytics Biotech to participate in a Panel Presentation at Canaccord Genuity s Horizons in Oncology Virtual Conference
AQ
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
NE
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
AQ
Oncolytics Biotech Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference
AQ
Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments
NE
Oncolytics Biotech Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
AQ
Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
PR
Oncolytics Biotech Appoints Patricia S. Andrews to its Board of Directors
AQ
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
PR
Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ONC Stock
  4. News Oncolytics Biotech Inc.
  5. Press Releases